Treatment with this monoclonal antibody in the DEFA1/DEFA3 risk-variant transgenic mice, but not in the mice with other genotypes, indeed dramatically improved endothelial barrier function and protected mice from sublethal sepsis, suggesting a precision medicine approach to enable targeted therapeutic intervention to improve sepsis outcomes. Here, DEFA3 is linked to Sepsis.